Arcus Biosciences (RCUS) Expected to Announce Earnings on Wednesday

Arcus Biosciences (NYSE:RCUS) is expected to be posting its quarterly earnings results before the market opens on Wednesday, February 19th. Analysts expect Arcus Biosciences to post earnings of ($1.20) per share and revenue of $31.31 million for the quarter.

Arcus Biosciences Trading Up 2.8 %

Arcus Biosciences stock opened at $13.05 on Tuesday. The stock has a market cap of $1.19 billion, a P/E ratio of -4.14 and a beta of 0.84. Arcus Biosciences has a fifty-two week low of $11.55 and a fifty-two week high of $20.31. The firm’s fifty day moving average price is $14.41 and its 200-day moving average price is $15.66. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24.

Insider Transactions at Arcus Biosciences

In other Arcus Biosciences news, CFO Robert C. Goeltz II sold 3,594 shares of the firm’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total value of $53,910.00. Following the completion of the sale, the chief financial officer now directly owns 60,138 shares in the company, valued at $902,070. This trade represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 12.30% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. HC Wainwright reissued a “neutral” rating and issued a $20.00 target price on shares of Arcus Biosciences in a research note on Wednesday, November 6th. Barclays upped their price target on shares of Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a research report on Friday, October 25th. Finally, Wedbush restated an “outperform” rating and set a $36.00 price target on shares of Arcus Biosciences in a research report on Thursday, November 7th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $32.67.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.